Do you use rectal douches? Or don't you?

Do you use rectal douches? Or don't you?
Take it whether you douche, or not! Click for survey in English, Español, French, Portuguese, Thai, Chinese or Russian.

Tuesday, June 30, 2009

India Poised to Decriminalize Gay Sex


via Edge Boston, by Kilian Melloy

Among the relics left behind in India by British colonialism is a law punishing consensual sex between adults of the same gender. But that may be about to change.

The Indian Penal Code embraced the law against sexual relations between individuals of the same gender, a holdover from the days when Britain wrote the laws for India. Earlier attempts to repeal the law, which prescribes prison sentences of up to a decade for gay sex, have been unsuccessful, reported a June 29 article in the Pakistan newspaper the Daily Times.

But government officials have indicated that they are willing to reconsider the ban on gay sex. One driving motive is a need to curb the spread of HIV and AIDS, which afflict an estimated two and a half million people in India.

The decriminalization of gay intimacy could bring more people in for testing and encourage gays to learn about safer sexual practices.

Meantime, at least one member of the Indian royalty, a gay prince, has spoken approvingly of the possibility that the law might change.

A June 30 article in The Hindustan Times reported that Manvendrasinh Gohil spoke out, saying, "It’s a very positive and encouraging initiative taken by the Central Government.

"I really appreciate the fact that the Home Ministry convened a meeting in this regard," Gohil added, going on to state, "I am hopeful about a positive outcome and justice to us," the article reported.


Read the rest.


L.A. County sheriff considers expanding condom distribution in jail


via Los Angeles Times, by Ari B. Bloomekatz

Inmates call Ron Osorio "West Hollywood" because the words are printed on the cream-colored cloth bag he carries inside Men's Central Jail each Friday.

The bag is filled with 300 Lifestyle condoms. Osorio, who works for the nonprofit Center for Health Justice, has been visiting the jail almost weekly since 2001, when Los Angeles County Sheriff Lee Baca approved a small but groundbreaking program that allowed the health group to pass out prophylactics to inmates in a segregated unit for gay men.

"We go to the dorms and a guy hands out the bagged lunches. There's another guy that hands out the juice. . . . and I stand between those two as they go through the line. They get their lunch, they get a condom, and they get their juice," Osorio said.

Not all inmates take condoms, but Osorio talks to those who do about the risks of HIV/AIDS.

Read the rest.

There are no gay pride parades in Jamaica


via Worldfocus

Lisa Biagiotti is working on signature stories for Worldfocus on HIV/AIDS and homophobia in Jamaica. She reported with Producer Micah Fink and Director of Photography Gabrielle Weiss, both from the Pulitzer Center on Crisis Reporting. Their reports will air on Worldfocus later this summer. Lisa gave the below interview to Thirteen.org.

Q: Gay pride is celebrated across the U.S. every June. Could there be similar celebrations of gay pride in Jamaica?

Lisa Biagiotti: No, there could not be an openly gay pride parade on the streets of Kingston, Jamaica, as in New York or San Francisco. In Jamaica, anti-sodomy laws criminalize sex between men, fundamentalist interpretations of the bible and pride in reproduction contribute to the general disdain and non-acceptance of the gay lifestyle.

Read the rest.


Monday, June 29, 2009

Uganda to Reintroduce Female Condoms


via RH Reality Check,
by Serra Sippel


When a man comes up with excuses for not using a male condom, women have a right to introduce their own tool for protection.

- Deusdeait Kiwanuka, Project Coordinator, Safe Homes and Respect for Everyone (SHARE)


Deusdeait's words poignantly capture a major challenge in fighting HIV/AIDS: to ensure women have access to prevention tools designed to put them in charge and give them an opportunity to initiate protection. Enter the female condom - the only safe and effective prevention tool that is designed for women to initiate and is available for use NOW. But "available for use" doesn't necessarily translate into "accessible to women" - whether in the U.S. or abroad.

Consider Uganda, where the Ministry of Health reports that 76% of the country's new infections are sexually transmitted and women make up 60% of those infected. Moreover, 42% of new infections occur in marital sex. These sobering statistics cry out for expanding prevention options that put women in the driver's seat. Despite this, women and their partners currently have no access to female condoms in the country.

Read the rest.


A condom specifically for anal intercourse?

IRMA chats up Dan Resnic of Strata Various Product Design about the ORIGAMI Condom - a new product in development designed specifically for anal intercourse.



IRMA - Tell us about this ORIGAMI condom you are working on. What is it? How is it different from other condoms?

DAN RESNIC
- This is a radical new design concept, made of non-latex material and the first AI (anal intercourse) condom data ever presented to the FDA for review. The data will be used to help establish the first safety standards for a condom used exclusively for AI. ORIGAMI Condoms are designed foremost for the pleasure of both partners and simultaneously to improve safety. Its improved capacity for better sensation during AI is intended to increase consumer acceptability and to promote its consistent use among men and women currently at risk.

The non-latex material we developed is unique. It's been lab tested as a male condom against a leading brand of a male latex condoms. The ORIGAMI material had zero viral permability compared with the latex condom, which had 5% viral permeability. Viral permeability is tested by introducing virus smaller than HIV into sterile water inside the condom, suspended in sterile water for 72 hrs. The water outside the condom is then tested to detect virus that may permeate through the condom. The test is repeated in reverse, starting with virus outside the condom then testing for viral premeability in the opposite direction. The tests are repeated again with pinholes punctured into the condoms. Again, the ORIGAMI tested at zero viral permeability even with puncture holes while the latex condom failed. In addition, the new material will not degrade in sunlight as does a latex condom and, after accelerated aging tests, it is expected to offer an extended shelf life of 10-12 yrs.

Future condom studies currently under funding review include a new, reusable ORIGAMI elastomer material we developed that can be washed and dried in a washer/dryer at high temperatures and can even be sterilized in a microwave or boiling in water and air dried in sunlight without compromising its structural integrity. The latter could be especially significant in regions like Africa and India where cost and distribution can be issues that prevent consistent condom use.

Photos and further details will be made available following FDA pre-market approval.


I – Where is the research at the moment?


DR
- Phase 1 research will begin next month, in July 2009, with the Behavioral Epidemiology Research Group at the UCLA Dept of Epidemiology, with co-Investigator Dr. Pamina Gorbach. R&D will be supported with the assistance of male and female consultants from design, medical and commercial sectors. The optimal design will undergo pre-clinical testing, with modified structural testing crietria appropriate for the higher stress in AI use. Clinical research will follow with study groups and data will be analized for final reports.


I – How are you collaborating with the NIH and UCLA? What is the timeline?


DR - As the PI for the project, I've awarded a sub-contract to UCLA, which will conduct the clinical research with volunteer couples who will test the condom in a unique study design developed by Dr. Gorbach, who heads the Behavioral Epidemiology Research Group at UCLA. The project has been funded by a substantial grant from the NIH. The study will run for 18-24 mos. starting July 1st. Subsequent Phase II research will take the project through to the end
of 2014, when the data can be reviewed by the FDA. Since there is no existing precedent the data cannot be reviewed under FDA's 510K application. Consequently, the process is much longer and much more expensive. The same is true of the ORIGAMI Female Condom we've developed. The FDA requires 3-4 similar products approved on the market before a similar device can be reviewed under a 510K application, which is typically a 90 day review process.


I – Why is it so important to have a condom specifically designed for anal intercourse?

DR- This is an excellent question. It would appear to many to be a frivolous and unnecessary product, however, the typical rolled condom design we are all familiar with, has not been tested for anal intercourse (AI), yet its the only means of protection available to men and women who engage in AI. The FDA states that condoms are the ". . . best available protection for anal sex..." although, to date, no data has been submitted to the FDA for review to support its use for AI.


I – Since unprotected anal intercourse is the most efficient means of sexual transmission of HIV, and since many people don’t use traditional condoms during anal intercourse each and every time, it seems odd that a condom like ORIGAMI hasn’t been thought of before. Why do you think that is?

DR
- Inventive ideas for new condoms that address specific needs such as AI have been consistently inhibited by the high cost of R&D as well as the socio/political barriers that existed until 2008. It wasn't until the concept of a female condom emerged that it was even possible to consider an inseted anal condom. For many years people had tried using the female condom for AI but it's not strong enough and it's lacking the unique design features compatible with AI.

Essentially, condoms are tested and FDA approved for vaginal use only. The FDA is typically provided with testing documentation from condom manufacturers based exclusively on vaginal use, and consequently there are no established guidance documents available from the FDA for condoms used for AI. For many years, in the US and elsewhere, it was considered taboo to discuss AI. In recent years, the subject was discussed at a special summit conference conducted by the FDA, specifically intended to encourage manufacturers to produce condoms for AI, however, none of the manufacturers who attended the meeting followed through. No existing condom manufacturer would risk producing such testing data as the failure rate for breakage, leakage and viral permeability would be significantly higher than testing results for vaginal use.

The FDA relies on manufacturers to present data for their review. Unless a manufacturer submits data (of any medical device) for review, the FDA does not conduct independent testing. As a regulatory agency, they are authorized only to review data from manufacturers but the agency cannot conduct its own independent research to set guidelines. It would be cost prohibitive to cover all medical devices. FDA Guidance Documents are established over time based on existing products and related testing data provided by manufacturers. Regarding latex condoms, the most current guidance document for manufacturers was last updated with minor changes on November 14, 2005.


I – Next steps?


DR
- We anticipate successful Phase I study data by June 2011, which we intend to follow with a larger, Phase II study. We will work closely with the FDA to help determine further testing criteria appropriate for condoms used for AI. For example, the breakage standards, not yet established for AI, will be significantly different from existing condoms designed and sold for vaginal intercourse. AI condoms must meet a higher safety standards than typical existing condoms that were originally designed in 1918 for vaginal sex.


Thank you Dan! We look forward to learning more about this important work.

Saturday, June 27, 2009

HIV travel ban to be lifted?


via Advocate.com, by Kerry Eleveld

The first step to ending the HIV travel ban in the United States has been taken by the Obama administration. The Office of Management and Budget posted a notice on its site Friday afternoon indicating that the department of Health and Human Services could move forward with steps to change a regulation that has restricted HIV-positive people from gaining entrance into the United States.

Read the rest.

Farrah's gift - outing the tumor that dare not speak its name


via San Francisco Chronicle, by Doc Gurley

Even now, most of Farrah Fawcett's obits genteelly - and obtusely - refer to her terminal illness as merely "cancer." Three years ago, when she was diagnosed, Farrah Fawcett's illness was marked with secrecy because of her tumor's location and type. Rectal/anal* cancer is one of the few remaining malignancies whose victims still continue to suffer twice - both from the disease, and the stigma.

Not so long ago, women similarly got tumors in their "female organs" - at least they did where I grew up in the South. That kind of secrecy left listeners not knowing even if people were talking about an above-the-waist disease, or a below-the-waist disease. We can all agree that voyeurism is an ugly human trait, and valid points could be made about whether anyone has a right to know that much detail about anyone's illness. But we have since discovered, thanks to Magic Johnson, Katie Couric, and others, that de-stigmazing body parts and illnesses can, literally, save lives.

The same is true for rectal/anal cancer. And Farrah Fawcett suffered in front of the camera, playing out her battle with disease, and even her decline - and, by doing so, outing her serious illness.

Read the rest.


Friday, June 26, 2009

Uganda: Prisons Chief - Sodomy is My Biggest Headache


[a truly frightening, hateful article]


The Uganda Prisons chief is warning that homosexual behaviour, an indigenously vile and illicit act, is growing among prisoners, heightening the risk of faster HIV/Aids spread at confinement facilities countrywide.

In an exclusive interview on Thursday, Dr Johnson Byabashaija, the commissioner general of Uganda Prisons, attributed the upsurge in the vice to sexual starvation among inmates and general moral rot on Uganda’s streets.


“People who come to prison come from the local communities,” he said. “If there are homosexuals in society, there will definitely be homosexuals in the prisons.”

And he added: “Cases of homosexuality, especially sodomy in “prisons are of two types; sodomy by consent and that by coercion. Sodomy by coercion, I think, is almost non-existent but the one by consent, I know, is definitely there.”

The catch-22 for authorities though, is how to employ known scientific preventive methods, including condom use, to scale down the worrying trend of sexual infections without violating any law or attracting government denunciation. They are doing the talking but the awareness campaign needs to be matched with tangible action for optimum results.

Giving out condoms to prisoners the way it is distributed to free men, said Dr Byabashaija, and could imply the discreet approval of homosexuality by Uganda Prison services.

Read the rest on Sunday Monitor.

Let's all start sucking around!

by Jan Wijngaarden

Fridae’s Men’s Sexual Health columnist Jan Wijngaarden wonders why oral sex has not been as widely recommended as a 'safer option' given that it has been found to be of much lower risk compared to anal sex.

A while ago, a friend of mine, who is around 55 years old and from Europe, sadly looked back on his life during a birthday dinner. He said that none of his (gay) friends from when he was in his twenties and thirties was alive to celebrate his birthday with him. They had all died - most of them, by far, died of AIDS.

I was intrigued. Why did he survive? Was he immune, or what? Or was he the only one who used condoms? When we were alone, after the dinner was finished, I decided to ask him.

He said: "Condoms? Nobody used them at that time. It was true; I had syphilis, gonorrhea and chlamydia several times, but those could be treated easily. That was not it, for sure."

So, what then? He answered: "It is the fact that I HATE anal sex which must have saved my life!"

It is an interesting conclusion, with a lot of truth in it. Anal intercourse is the sexual behaviour which is - by far - most likely to transmit HIV among gay men (and - much less well known - maybe among some heterosexuals, too).

Read the rest.


Thursday, June 25, 2009

Male circumcision - what's the latest?


It has been two years since the World Health Organization recommended male circumcision (MC) as an HIV prevention measure, and countries in Southern Africa - the region hardest-hit by AIDS - have been slowly gearing up to provide widespread access to the procedure.

IRIN/PlusNews has compiled a list of the progress made so far in eight southern African countries.

Read the rest.

AIDS denial: A lethal delusion


The effects of AIDS denialism in Africa are no joke, however. In 2000, as the movement was rapidly losing all credibility, South African president Thabo Mbeki asked some of the leading denialists to sit on an advisory council to guide his response to the epidemic. On their advice he did everything in his power to resist ART use in his country.


via New Scientist, by Jonny Steinberg

ON 27 December 2008, a well-heeled 52-year-old woman died in a Los Angeles hospital. Her death certificate describes a body riddled with opportunistic infections typical of the late stages of AIDS. Christine Maggiore had tested HIV positive 16 years earlier, but she had shunned ART, the antiretroviral therapy that stops HIV replicating and prevents AIDS.

This was not the first time a death in Maggiore's family had made headlines: five years earlier her 3-year-old daughter Eliza Jane had died. The autopsy described a chronically ill little girl who was underweight, under-height, and had encephalitis and pneumonia - all AIDS-related. When pregnant, Maggiore had again rejected ART and she had breastfed Eliza Jane, another way of transmitting the virus.

Why, in 21st-century California, would a middle-class woman and her young daughter die like this when there is tried-and-tested treatment for their illness? The answer lies in a bizarre medical conspiracy theory that says AIDS is not caused by HIV infection (see Five myths about HIV and AIDS).

It is tempting to dismiss the so-called AIDS denialism movement out of hand, but it has a strong internet presence, with a plethora of websites and blogs that can mislead the unwary. While the movement has lately suffered some significant blows to its credibility, it has in the recent past wielded extraordinary influence, especially in southern Africa, the centre of the world's AIDS epidemic. "Denialism has been relegated to the fringes of the internet, but it isn't of no consequence," says John Moore, an immunologist at Weill Cornell Medical College, Ithaca, New York, and one of the world's foremost AIDS researchers. "It can still cost the lives of unsuspecting people."

Read the rest.

Similar rises in gay men’s HIV diagnoses seen in Western Europe, North America and Australia since 2000


via Aidsmap, by Roger Pebody

A comparative analysis of HIV diagnoses in gay men in eight industrialised countries has found that while they decreased between 1996 and 2000, diagnoses went up by 3% a year from 2000 to 2005, researchers report in the June 2009 issue of the Annals of Epidemiology.

The researchers used national surveillance data compiled by public health bodies in the UK, the Netherlands, France, Germany, Spain (Catalonia only), Australia, the United States (25 states only) and Canada. These countries were chosen as a convenience sample of concentrated epidemics where the surveillance systems were broadly comparable (although not identical) and did not change too much during the period studied.

Read the rest.

Tuesday, June 23, 2009

IRMA ALC announces "Acceptability of Rectal Microbicides (RM): Barriers and facilitators of RM use among MSM in 4 South American Cities"





English:

IRMA-ALC (America Latina y el Caribe) founding members Jerome Galea (UCLA Program in Public Health, Latin America); Jórge Sánchez (INMENSA - Peru), Orlando Montoya (Equidad – Ecuador) and Beatriz Grinsztejn (Fiocruz – Brazil) are excited to announce funding received from the UCLA AIDS Institute and the UCLA Center for AIDS Research for a new project entitled, “Acceptability of Rectal Microbicides (RM): Barriers and facilitators of RM use among men who have sex with men in 4 South American Cities.”

This study will be the first of its kind to systematically explore RM in the region among diverse populations including both gay and non-gay identified men who have sex with men, sex workers and transgendered persons. The study will take place in Lima and Iquitos Peru; Guayaquil, Ecuador; and Rio de Janeiro, Brazil and will involve key-informant interviews, one-on-one in depth interviews, focus groups and conjoint analysis (a quantitative method that helps to understand consumer preferences) to assess the acceptability of using RM and willingness to participate in and feasibility of future RM clinical trials.

The project will also examine culture-specific customs, beliefs, and stigma related to anal sex. In all up to 256 people will participate.

Galea said, “We hope that the data collected in this study will provide the foundation for a future, larger research agenda leading to the development of RM clinical trials in the region, as well as expanded acceptability studies, specifically with respect to RM delivery devices which will be critical in preparing for adequate roll-out and dissemination of RM.

en español:

Los miembros fundadores de IRMA-LAC, Jerome Galea (Programa de Salud Pública de la UCLA en América Latina), Jorge Sánchez (INMENSA – Perú), Orlando Montoya (Equidad - Ecuador) y Beatriz Grinsztejn (Fiocruz - Brasil) se complacen en anunciar el financiamiento recibido del Instituto
de Sida de la UCLA y el Centro para la Investigación en Sida de la UCLA para un nuevo proyecto titulado “Aceptabilidad de los Microbicidas Rectales (MR): Barreras y Facilitadores para el Uso de MR entre Hombres que Tienen Sexo con Hombres en 4 Ciudades de Sudamérica”.

Este estudio será el primero en su tipo en explorar sistemáticamente el uso de MR en la Región en diversas poblaciones, incluyendo a hombres que tienen sexo con hombres con y sin identidad gay, trabajadores sexuales y personas transgénero. El estudio será realizado en Lima e Iquitos, Perú; Guayaquil, Ecuador; y Río de Janeiro, Brasil, e incluirá entrevistas con informantes clave, entrevistas en profundidad, grupos focales y un análisis conjunto (que involucra el empleo de un método cuantitativo que ayudará a entender las preferencias de los usuarios), para evaluar la aceptabilidad del uso de MR, la viabilidad de futuros ensayos clínicos de MR, y la voluntad de las personas para participar en ellos.


El proyecto examinará también las costumbres específicas a la cultura, creencias y estigma relacionado con el sexo anal. En total, participarán hasta 256 personas.


Al respecto, Galea señaló: “Esperamos que los datos recolectados en este estudio sienten las bases para una agenda de investigación posterior de mayor envergadura, que conduzca al desarrollo de ensayos clínicos de MR en la Región, así como a estudios de aceptabilidad mayores, específicamente sobre los dispositivos de aplicación de MR, estudios que serán cruciales en la preparación de la implementación y diseminación de los MR.

SOUTH AFRICA: A mixed bag of new HIV figures

via PlusNews

Young men have made a decision that they're going to run around, but that they're going to use a condom.

The percentage of people living with HIV in South Africa has barely changed in the last six years, but new data released on Tuesday revealed that between 2002 and 2008 there were many changes in HIV knowledge, risk behaviour and testing habits.

The third national HIV prevalence, incidence and communication survey, conducted in 2008 by the Human Sciences Research Council (HSRC), in conjunction with the Medical Research Council (MRC) and the Centre for AIDS Development, Research and Evaluation (CADRE), has given researchers the first real opportunity to study trends in HIV prevalence and risk behaviour. Previous surveys were conducted in 2002 and 2005.

The findings, based on interviews with about 21,000 individuals, 15,000 of whom agreed to anonymous HIV tests, give a fairly detailed picture of South Africa's mixed success in fighting the largest HIV epidemic in the world.

Prevalence appears to have stabilized at about 11 percent, and infection rates among children and teenagers have decreased, but have increased slightly in adults over the age of 25.

Olive Shisana, CEO of the HSRC and one of the survey's principal investigators, noted that African women aged 20 to 34, remained the group most at risk with a stubbornly high HIV prevalence of nearly 33 percent; men aged between 25 and 49, with an infection rate of 24 percent, have the second highest risk profile.

Read the rest.


Monday, June 22, 2009

Treatment as prevention rejected by French ministry of health


via Aidsmap, by Roger Pebody

The endorsement of treatment as prevention by the French National AIDS Council has been dismissed by the country’s ministry of health.

In April, the National AIDS Council (Conseil National du Sida) issued a lengthy and nuanced analysis of the potential impact of greater use of antiretroviral treatment on HIV transmission and prevention. It recommended campaigns to raise awareness of the benefits of HIV testing and earlier treatment, and that negative messages about side-effects and pill burden should receive less emphasis.

The National AIDS Council is independent body of experts (academics, clinicians, politicians etc.) who are nominated by various parts of the government. It has a consultative role.

However a press statement issued by the Direction générale de la santé (the section of the health ministry responsible for public health) rejected the National AIDS Council’s analysis.

The statement insisted that only male or female condom use could guarantee a maximum protection against HIV and other sexually transmitted infections, and that condoms must be used consistently during casual sex or when the HIV status of a stable partner was not known. The statement said there was no conclusive evidence concerning men who have sex with men, the efficacy of antiretroviral treatment as a sole prevention strategy or the risks of resistance if more people took treatment.

The ministry announced that a new group of experts would be asked to reconsider treatment as prevention as part of their review of HIV prevention strategies. The opinions of this group are likely to feed into France’s next three-year HIV strategy.

The campaigning group The Warning denounced the conservatism of the Direction générale de la santé. They said that the health ministry “remains silent” about the residual infection risk associated with condom use, and did not address the issue of the growing number of people who don't use a condom, either some or all of the time. “They show that they still believe it is possible to put into place a prevention strategy that takes no notice of the choices and behaviours of individuals,” the group commented.

Studying and Stopping Rectal Transmission of HIV

Anal intercourse is a key mode of HIV transmission, not only for MSM but for many women.


by Jeffrey Laurence, M.D.
via amFAR

June 17, 2009—In recent years, several large clinical trials of microbicides designed to block penile-vaginal transmission of HIV have been completed. Limited, if not definitive success was obtained with only one product, PRO2000. Other products are in various stages of testing in women. But similar large trials have not been conducted with rectal products, despite the fact that anal intercourse is a key mode of transmission, not only for men who have sex with men but for many heterosexual women. Research by two amfAR-funded groups is yielding new information critical to the design and testing of rectal microbicides.

Writing in the May issue of the Journal of Experimental Medicine, amfAR fellow Dr. Brandon Keele of the University of Alabama, along with colleagues from six other research institutions, developed a model in rhesus macaque monkeys for rectal transmission of SIV, the monkey AIDS virus, and compared their results with HIV transmission in humans. Dr. Keele uncovered striking similarities between monkeys and people in terms of the amount of virus required for infection, the types of viruses later found in the blood, and immune response. These findings validated his system as a representative model with which to test strategies to inhibit rectal HIV transmission.

In order to infect the macaques, Dr. Keele used a mix of SIV viruses that closely mimicked the limited genetic diversity of viruses present in humans early after an infection. This is important, as people who are recently infected have very high levels of virus in their genital fluids and blood, and are more likely to transmit HIV during this stage of infection than in others. Regardless of whether a monkey was inoculated intravenously or rectally, within one to five weeks the viruses growing in the blood of all infected animals were similar, and represented progeny of just a single infecting virus. This is exactly what happens in people. Also reflecting the human situation, direct intravenous injection of SIV into monkeys was 2,000 times more efficient at originating an infection than rectal inoculation. And increasing the dose of virus increased the infection rate.


amfAR fellow Dr. Carolina Herrera (above), working at St. George’s University in London, took another approach to understanding rectal transmission. Using a test tube system involving human tissues, she sought to define the best cocktail of known anti-HIV drugs to include in a rectal microbicide.

In a report in the May issue of the journal Antimicrobial Agents and Chemotherapy, Dr. Herrera and colleagues studied both human cell lines as well as small pieces—about a tenth of an inch—of human intestine obtained from HIV-negative patients undergoing surgery. Like isolated cells, these “colorectal explants,” maintained in nutrient broths atop foam rafts, can be infected with HIV. Dr. Herrera asked what would happen if various combinations of anti-HIV drugs—a reverse transcriptase inhibitor and two non-nucleoside reverse transcriptase inhibitors—were added to the cells or tissues.

The results of her study indicated that various combinations of the three drugs proved much more effective in blocking HIV infection than any single drug. Combinations were also key to inhibiting infection by drug-resistant viruses. “These findings may have important implications for the rational design of effective rectal microbicides,” Dr. Herrera suggested. Considered in conjunction with the work of Dr. Keele and many other groups, her conclusion seems accurate.

These and other approaches, both clinical and behavioral, were the topic of an amfAR-sponsored think tank held in mid-March.

To read more and view a video summary of that conference, click here [IRMA's Jim Pickett participated in this think tank.)

Dr. Jeffrey Laurence is amfAR’s senior scientific consultant.

Saturday, June 20, 2009

IRMA follows Iranian protests



Up to the moment reporting on the Iranian protests, via Twitter, YouTube, and more

Check out:

The Daily Dish by Andrew Sullivan

Live blogging on the Huffington Post by Nico Pitney


Friday, June 19, 2009

IRMA NIGERIA holds Microbicides Sensitization Forum


SENSITIZATION PROGRAM FOR HIV/AIDS SUPPORT GROUP, SEX WORKERS AND SOME HEALTH WORKERS IN ALIMOSHO LOCAL GOVERNMENT, LAGOS STATE, NIGERIA.

IRMA NIGERIA organized a sensitization program on Microbicides development on the 6th of June, 2009.

Report by Kadiri Audu
IRMA Steering Committee member




Attendance
:

HIV/AIDS Support group 32 people

Sex workers 20 people

Health workers 9 people

Total 61 people



Aim: To create awareness about Microbicides Development and to encourage the participants to get involved in the process.

Analysis: Questionaires were administered at the event to estimate the level of awareness of participants about Microbicides Development.

o 57% of the participants have never heard about Microbicides.
o 15% heard about it but require more information
o 15% heard about it but do not know what it is or how it works.
o While 13% are familiar with Microbicides development.

Some of the questions asked at the event were:
o When would Microbicides likely to be available?
o How much would it cost?
o Would it be supplied for free?
o How are trial volunteers recruited?
o What if I want to volunteer?

Outcome: The outcome was quite encouraging because all the participants showed a level of understanding and 38 people joined IRMA NIGERIA.

Presentation: The paper presented at the event is below.


PAPER PRESENTATION: MICROBICIDES SENSITISATION SYMPOSIUM

ORGANISED BY IRMA NIGERIA

WHAT IS MICROBICIDES?
Microbicides are products that could be applied vaginally and that would reduce the transmission of HIV during sexual intercourse. A Microbicides could take the form of a gel, film, suppository, sponge, cream, vaginal ring or other delivery method that releases the active ingredient gradually.

THE NEED FOR MICROBICIDES:
Giving women power over AIDS. The power for women to enjoy safe sex, without negotiating with a sex partner.

KEY ISSUES IN MICROBICIDES DEVELOPMENT:

• Timing – if the handfuls of Microbicides candidates that are currently in advanced clinical trials prove to be effective, a Microbicides could be ready by the end of 2010.

DRUG DEVELOPMENT:
Drug development generally, is a long and complicated process. It takes 10 – 15 years between discovery of a promising lead and its availability on the market.
• Many candidates fail before one ever proves both safe and effective.
• The development stage needs many different candidates which use different mechanisms of action.

MAKING MICROBICIDES AVAILABLE TO PEOPLE LIVING IN THE DEVELOPING WORLD:
• The Microbicides field is committed to making the product available to firstly, those who need them most.
• Public sector developers and advocates are working hard to ensure that innovative vaccines and Microbicides will be accessible and affordable to the people who need them most.
• It is possible that Microbicides would be licensed first in a country where HIV prevalence rate is high rather than countries with low risk.

NATURE OF CLINICAL TRIALS:
• Pre-clinical trials – This is a stage where identified Microbicides candidates pass through a series of rigorous tests in a laboratory and animals before they are allowed to be tested on human beings.

Clinical trials:
• Phase I – phase I trials are conducted to determine whether the product is safe if used by a small number of volunteer participants over a few weeks, usually 1-3 weeks with 20 – 30 participants
• Phase II – phase II also test for safety of the product but over a longer period of time and with a larger number of participants; 6-18 months, 200-400 participants
• Phase III – phase III trials measures effectiveness; that is weather or not Microbicides actually works in the course of normal use to prevent HIV and STIs. 1-2 years, thousands of participants are enrolled at this stage.
NOTE:
• Frequently, clinical trials need to be repeated to confirm their result or to test the findings in different population.
• The product must be reviewed and licensed for use by at least one drug regulatory agency.

RECTAL MICROBICIDES:
These are products that could be applied rectally and that would reduce the transmission of HIV during anal intercourse and prevent infection.

THE NEED FOR RECTALMICROBICIDES:
• Vaginal Microbicides might not be safe for rectal use
• There are people who engage in anal sex world over

ISSUES AROUND RECTALMICROBICIDES:
• Stigmatization
• Human rights
• Rectal safety of vaginal Microbicides


Thursday, June 18, 2009

Laos tackles transgender taboos

I just want to be accepted and
not separated from the rest of society.

via BBC News

A new drive to contain the spread of HIV/Aids in Laos is forcing officials to recognise a marginalised group - transgender men known as "katheoy". The BBC's Jill McGivering went to meet some of them in the capital, Vientiane.

Khom was born male.

But she has thought of herself as female since she was about nine years old.

Now 28, she could easily be accepted as a woman. She has long, styled hair, make-up, and a gentle, feminine manner.

But when she talks about her experiences of being "katheoy" in Laos, her voice is solemn. They're not fully accepted, she says.

She uses the example of trying to find a job. If she fills in an application form, it always needs a photograph as well. The selectors look at his gender - "male" - and at the photograph. It goes in the wastepaper bin, and she never gets called for interview.

High-risk

But after being largely ignored for so long, katheoys like Khom are suddenly the focus of attention from the Lao government. Some are "long-haired" katheoys like Khom, who present themselves as women. Others are "short-haired" katheoys who present themselves as men.

Both groups have sex with men.

They have emerged as the country's highest risk group for HIV/Aids - and are now the target of a special campaign.

Read the rest.

Wednesday, June 17, 2009

Anal squamous intraepithelial lesions among HIV-positive and HIV-negative men who have sex with men in Thailand

Li AH, Phanuphak N, Sahasrabuddhe VV, Chaithongwongwatthana S, Vermund SH, Jenkins CA, Shepherd BE, Teeratakulpisarn N, van der Lugt J, Avihingsanon A, Ruxrungtham K, Shikuma C, Phanuphak P, Ananworanich J.

Vanderbilt University School of Medicine, TN, United States.

Abstract.

OBJECTIVES: To evaluate the prevalence and risk factors of anal squamous intraepithelial lesions (ASIL), the putative anal cancer precursor, in Asian HIV-positive and HIV-negative men who have sex with men (MSM).

METHODS: Men who underwent anal Pap smear reported clinical, sociodemographic, and behavioral information collected through questionnaire and interview between January 2007 and April 2008. Chi-square test and logistic regression were used to evaluate ASIL prevalence and risk factors among HIV-positive and HIV-negative MSM.

RESULTS: Of the 174 MSM (mean age 32.1 years), 118 (67.8%) were HIV-positive MSM. Overall, 27% had abnormal anal cytology: 13.2% had atypical squamous cells of undetermined significance (ASC-US), 11.5% had low-grade squamous intraepithelial lesion (LSIL), and 2.3% had high-grade squamous intraepithelial lesion (HSIL). Prevalence of ASIL was higher among HIV-positive than HIV-negative MSM (33.9% vs 12.5%, p=0.003). Among HIV-positive MSM, 16.1% had ASC-US, 14.4% had LSIL, and 3.4% had HSIL. These were 7.1%, 5.4%, and 0% in HIV-negative MSM, respectively. Anal condyloma was detected in 22% of HIV-positive and 16.1% (9/56) of HIV-negative MSM (p=0.5). In HIV-positive MSM, anal condyloma (OR 3.42, 95% CI 1.29 to 9.04, P=0.01) was a significant risk factor for ASIL. Highly active antiretroviral therapy (HAART) use and CD4+ T-cell count were not associated with ASIL.

CONCLUSIONS: One-third of HIV-positive and 12.5% of HIV-negative MSM had ASIL. Thus as greater numbers of HIV-positive MSM live longer due to increasing access to HAART worldwide, effective strategies to screen and manage anal precancerous lesions are needed.

Monday, June 15, 2009

POZ Flashback - Beyond Condoms: Life After Latex


[See how far we've come - or not - in the last 10 years.]


Yet amidst this growing pro-microbicide chorus, one omission goes unnoticed by all but a handful of angry critics who ask,

“What about microbicides for the rectum?”


Published June 1999

Beyond Condoms: Life After Latex

by Michael Scarce, for POZ

Microbicides weren’t our dad’s safe sex. But for us, they’re just a shout away

Countdown Y2K: Part 6 of a 12-Part Series

Imagine a world without condoms. I’m talking not about the cure, a widespread conversion to barebacking or mandatory castration, but a future in which rubbers are obsolete relics, replaced by an inexpensive, easy-to-use, anti-STD gel applied internally to the vagina or the rectum before sex. These “chemical condoms,” known as microbicides, would ideally inactivate a range of harmful bacteria, viruses and other bugs, revolutionizing safer sex as we know it. Contraceptive microbicides such as spermicidal films, foams and jellies have been available over the counter and by prescription for more than two decades. More recently, scientists have begun struggling to develop a similar technology to prevent infection with HIV and other STDs. By 2000, however, the Clinton administration’s $100 million, four- year initiative to develop such “topical agents” will barely even be slouching toward its goal.

As infection rates climb among women, especially in developing countries, the need for a low-cost, female-controlled form of protection has become urgent. Gender inequity within heterosexual relationships has long been a driving force for technology to balance the scales of sexual decision-making, and two organizations have formed in the United States to carry out this advocacy—Microbicides as an Alternative Solution (MAS), in Berkeley, California, and the Alliance for Microbicide Development, in Takoma Park, Maryland. “Because condoms are controlled by the man, both partners must agree to use them,” says MAS’s Bethany Holt, explaining her group’s quest for products that can be used exclusively by the receptive partner. AIDS service organizations worldwide have reported commonplace episodes of domestic violence triggered by disputes over condom use. Even in the absence of intimidation or force, many women have learned to defer their own pleasure and safety in favor of men’s desires. Yet amidst this growing pro-microbicide chorus, one omission goes unnoticed by all but a handful of angry critics who ask, “What about microbicides for the rectum?”

The most astonishing and reprehensible thing is, why, when the gay male community has so much to gain with this scientific development and so much to lose without it, we raise no voice to advocate for it.


Scientists and public health experts have long approached anal sex with a mix of anxiety, scorn and denial. Take, for example, the often-unacknowledged fact that the FDA has never approved a single condom or other device for anal sex. As the scientific agenda of safer sex seems to be guided more by morality than epidemiology, people who practice anal sex have been technologically abandoned.

Surprisingly, gay men have failed to rally for latex-free technologies that maximize pleasure in addition to safety. Dr. Clark Taylor, a senior researcher at the Institute for the Advanced Study of Sexuality, says, “The most astonishing and reprehensible thing is, why, when the gay male community has so much to gain with this scientific development and so much to lose without it, we raise no voice to advocate for it.”

With more than 50 microbicides now in the research pipeline, only one has entered FDA Phase I clinical trials for rectal use. A vaginal product will almost certainly be developed first, due to greater allocation of resources and the diversity of substances being tested. The strategies for developing an effective microbicide include: using detergents that disrupt viral membranes without harming healthy human cells; combining nonoxynol-9 with a seaweed extract to enhance its protective properties; using a liquid that clings to the vaginal lining and congeals to form a defensive coating; altering the body’s acidity to create an environment hostile to pathogens; and genetically engineering antibodies that prevent infection.

Resistance to designing a product specifically for anal sex makes the prospect of a rectal microbicide grim, not least because of basic anatomy. Unlike the vagina, the rectum is an open-ended cavity, making it difficult to thoroughly coat. There are also differences between ecologies of the vagina and rectum, raising questions of how microbicides might upset the body’s natural balance of helpful bacteria, pH levels and more.

But the political minefield of FDA approval poses even bigger problems. When the mainstream media caught wind, in 1996, of the only government-funded clinical trial in which gay men used rectal microbicides, a right-wing feeding frenzy ensued. Condemning the study, the Family Research Council said, “We are facilitating, at taxpayer expense, an illegal and immoral activity that’s abhorrent to most Americans.” Sodomy laws often provide a rationale for squelching any government act that might encourage safer anal sex. Such was the case with the Reality Female Condom. Formerly named “Aegis” and pitched as a gender-neutral barrier pouch for rectum and vagina, the device was restricted to vaginal use by the FDA, citing sodomy statutes as a deciding factor. Still, some gay men use Reality for anal sex.

The use of pharmaceutical products for unintended purposes related to sexual health is nothing new. The New York state health department published a 1992 brochure titled “For Women Only,” giving suggestions for noncondom alternatives to reduce the risk of HIV infection, arranged along a spectrum of safety. At the riskiest end, the brochure proposed the use of a spermicide alone as “better than nothing.” But the health department refused to make any recommendation about rectal use of the same nonoxynol-9 based product. Anal sex enthusiasts will be left to fend for themselves when it comes to microbicides, likely crossing the boundaries of gender- and anatomy-specific marketing to adopt yet another vaginal product for rectal use with little prior testing for safety. Taylor offers anecdotal reports of gay men already using over-the-counter contraceptive gels along with or instead of latex.

The profitability of microbicides, above all else, will dictate their likelihood of development and viability. Unlike other large-scale HIV prevention efforts, most funding for microbicides is concentrated in the private sector of the pharmaceutical industry. As with condoms and spermicides, the federal government regulates their marketing but is not responsible for their creation. This commercial enterprise necessitates pumping research dollars into a product that will eventually return a profit. Past lawsuits against drug companies for contraceptive failures make them gun shy about possible liability over HIV infection. And patents on many microbicide ingredients have expired, further narrowing profit margins.

Most of the researchers in this field aren’t just homophobic, they are erotophobic.

Although AIDS activists have become adept at pressuring drug companies to accelerate access to treatments, a similar approach to prevention technologies has yet to be organized with the same degree of sophistication. The vast majority of prevention work has concentrated on strategies for behavioral change, reinforcing a divide between prevention and treatment camps that mirrors the split between social and medical sciences.

Yet technologies such as nonlatex barriers are now beginning to spark prevention debates that echo past AIDS treatment struggles around industry accountability, corporate greed, the ethics of human experimentation, diversity of clinical trials participants and more. Even the recent trends in research draw a striking parallel with those of protease inhibitors. Scientists have begun to use a cocktail approach to boost the effectiveness of microbicides, struggling to produce a substance hostile to dangerous pathogens while less toxic to the body, as well as time-released versions that work longer with less dosing.

But don’t expect a David Ho of microbicides to emerge anytime soon. Because so few scientists are willing to tackle research on sex, let alone homosexuality or anal sex, the kind of collaboration enjoyed by treatment scientists is rare. Connie Celum, MD, a researcher at the University of Washington and principal investigator of the only study that has tested rectal microbicides in human subjects, says, “Most of the researchers in this field aren’t just homophobic, they are erotophobic.” With rare exceptions, sexuality as a field of scientific inquiry holds little promise for professionals looking for money and prestige.

As with past attempts to democratize science, political pressure for new sexual technologies must be initiated from outside as well as within. Past prevention has been bolstered by organizations specializing in behavioral studies, such as San Francisco’s Center for AIDS Prevention Studies, and advocacy groups like MAS have yet to formulate a comprehensive approach to prevention science. A group based on the model of Treatment Action Group (TAG) or Project Inform could advocate for new prevention, serve as a clearinghouse for the latest research and distill complex science into accessible information for the layperson to use in making more informed choices about risk, ranging from oral sex to instructions for using the Reality Female Condom for anal sex.

As the science of safer sex evolves, it becomes clear that women and gay men’s health are inextricably linked. Microbicides have presented both populations with the latest version of an all-too-familiar choice: Form a political partnership by finding ways to collaborate toward a mutually beneficial goal, or reinforce divisive competition along lines of gender and sexual orientation.

Unfortunately this choice has emerged in a time of escalating gender conflict within the epidemic. The percentage of male-to-male transmission among new infections is decreasing, while heterosexual transmission rises. Women of color, in particular, comprise the population of fastest-growing rates of infection. Within most AIDS organizations, however, white gay men still hold the purse strings.

Yet even if an effective microbicide is never found, the far-reaching implications for such a quest can already be felt. The needs of women, although still horribly underserved, are beginning to get the attention they deserve. And for the first time we have allowed ourselves to imagine life without latex, prioritizing pleasure along with safety. That alone is cause for celebration.

Source.

Thursday, June 11, 2009

Securing the Voice of MSM in Eastern Africa



by Larry Misedah
IRMA Steering Committee Member

Despite the recent visibility of African men who have sex with men (MSM), there is still a wide gap in intervention programs for this group categorized as one of the most at risk populationa in a country like Kenya, where (like other countries) same sex practices are still viewed with a lot of stigma and discrimination.

With recent moves by governments like Burundi, it has been rather a challenge to even have dialogue with policy makers on inclusion of MSM in National Programs for HIV/AIDS. In a bid to bridge this gap, the UNAIDS and UNDP have started a research effort whose overall aim is to develop strategies that can be employed to promote government-level organization and partners through the UN system to: encourage accelerated quality prevention and HIV and health care delivery for MSM, influence and affect HIV/AIDS and rights based policies relevant to MSM, strengthen capacity of communities and community building.

In a recent focus group discussion for Eastern Africa, there were representatives from the different countries in Eastern Africa, trying to secure a voice of African MSM within HIV and AIDS development policy and programming in Eastern Africa. Although Kenya seemed to be some steps ahead in terms of inclusion in the strategic plan as compared to neighboring Uganda, Tanzania, Rwanda and Burundi, there were still some commonalities within all the countries. Lack of political support, current limited efforts that are not evidence based, religious and cultural hostility, negative attitudes from service providers and inadequate or total absence of IEC material were some of the challenges sited.

In trying to come up with an action plan for the same, the participants from different countries also tried to identify some of the recommendations for the different countries. Perhaps of most significance was research, taking into consideration other factors i.e. leaving out of WSWs (women who have sex with women) in HIV/AIDS intervention programs because of lack of evidence, deeper understanding of the different ddentities for the African MSM ; notably, a vast majority of African MSM do not identify as being gay or bisexual hence being left out in the intervention programs, and carrying out efficacy studies on the different indigenous lubricants currently being used by MSM or other alternatives. It is important that we do not get stuck without a supply of lube - a major challenge.

With the different components that this research will take, it was a common concern of the participants that this would not just be one of those projects that would end up on the shelves. Dr. Theo and Dr. Vasu, who are dedicated researchers, strongly assured the participants this would not happen, with a strong back up from Shivaji Bhattacharya, the senior policy advisor for HIV and Human Rights UNDP aub-regional Office for East and Southern Africa, who further stressed the UN’s commitment to this process and the necessity to come up with a strong tool that can be used for advocacy at different levels.

Read more from Larry.

IRMA Member Proscovia Ayoo - Her mission is to bandage the wounds of HIV victims


via The New Vision (Uganda)

Proscovia Ayoo is a hero, not only to her family but to her community as well. Being ostracised because she is HIV-positive did not prevent her from joining the battle against the scourge. Samuel Senkaba brings you her struggles, fears and triumphs

BEFORE Prosscovia Ayoo took an HIV test, she could not imagine living with HIV. That all changed in December 1997, when she took a test and turned out to be HIV-positive. Ayoo felt like she had been handed a death sentence. “I wanted to commit suicide to spare my family from worrying about my health. However, because of the psychological pain involved, I abandoned the suicide mission.”

Today, she is singing a new song. “I’m glad for the gift of life, HIV is now part of me and life is still beautiful nonetheless.”

Read the rest of this article.

Read "I am called Ayoo Proscovia" on the IRMA blog.

Read her bio on the IRMA website.

IAS Investigates Washington D.C. as Host of 2012 International AIDS Conference


Washington D.C. could be the host city of the world's largest conference in the field of health and development if the United States drops its ban on the entry of HIV-positive people.

11 June 2009 (Geneva, Switzerland) - The International AIDS Society (IAS) today announced its interest in convening the International AIDS Conference in 2012 (AIDS 2012) in Washington, D.C.. The final decision would depend on whether the United States drops its 22-year old ban on the entry of foreigners living with HIV into the country.

"In recent years, the United States government's leadership on HIV/AIDS has been unparalleled on the global stage," said IAS President, Dr Julio Montaner. "This long-standing law, which is contrary to all scientific evidence and human rights principles, is one of the U.S.'s weakest spots in HIV policy," continued Dr Montaner.

"The IAS's opposition to the ban is rooted in its history as the convener of the International AIDS Conference. A fundamental principle of the IAS is that people living with HIV should be able to participate fully and without restrictions at HIV conferences. Hence, the conference has not been held in the U.S. since 1990 because of the ban on entry of people living with HIV," explained Dr Montaner.

Following the announcement in July 2008 that the U.S. government restrictions would be repealed, the Governing Council of the IAS expressed its intention to hold AIDS 2012 in Washington, D.C.

"Holding this conference in Washington , D.C. would be an opportunity to highlight the longstanding U.S. global leadership in HIV research, prevention, care and treatment, along with the ongoing domestic and international challenges to ending the epidemic. AIDS 2012 will bring together an estimated 30,000 participants from around the world to address one of the most critical health and development challenges of our generation, highlight the latest results of HIV-related research and foster new streams of collaboration to this global effort."

"Twenty-five years after the discovery of HIV, the world is finally making progress on rolling back the terrible toll of the global AIDS pandemic. It is time for the U. S. to end the discriminatory ban on entry of foreigners living with HIV," said Dr Montaner.

The U.S. is among only nine countries in the world that still ban foreigners from visiting and migrating specifically on the basis of an HIV-positive status. The others are: Brunei, China, Oman, Qatar, South Korea, Sudan, United Arab Emirates and Yemen. Despite Congressional repeal in July 2008 of the U.S. law, or "HIV entry ban" as it is commonly referred to, the actual regulatory policy that puts the ban into practice is caught up in government bureaucracy and remains in force.

IAS Executive Director, Craig McClure explained that scientific evidence shows travel restrictions against HIV-positive people are ineffective prevention tools.

"These laws are not consistent with current scientific knowledge, public health best practice, and humanitarian principles. Discriminatory laws and policies like this continue to fuel national and international stigma and do not protect public health. These laws sustain a culture of exclusion, rights violations and marginalization that impedes an effective response to the epidemic," said Mr McClure.

The IAS is the world's leading independent association of HIV professionals, with over 13,000 members in 188 countries working at all levels of the global response to HIV/AIDS. IAS members represent scientists, clinicians, public health, policy experts and community practitioners on the frontlines of the epidemic. The IAS is the lead organizer of the International AIDS Conference and the IAS Conference on HIV Pathogenesis, Treatment and Prevention.

Monday, June 8, 2009

Despite Strings, NIH Will Focus Money on Science

via Med Page Today, by Emily P. Walker

Although $10.4 billion allocated to the National Institutes of Health (NIH) in the economic stimulus bill is aimed at creating jobs, a top official said the agency will still fund projects based on their science, rather than their economic impact.

However, Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases, said NIH will change its scoring procedures with an eye toward projects that could conclude most of their research within two years.

That's because the money came with a hitch: the research should be short-term projects, or those most likely to deliver the most bang to the economy for the stimulus buck.

"In biomedical research, two years is a very short amount of time," Dr. Fauci said at a Monday presentation sponsored by the American Association of Medical Colleges on how NIH plans to spend the stimulus money.

"It's not like we're paying money to build a bridge from here to there and in two years it's finished," he said, referring to the ongoing nature of scientific discoveries.

Still, short-term projects, or those that will likely still have funding after fiscal 2010, are likely be favored.

Regardless of the strings attached, the cash infusion will be welcome for the agency whose funding has remained static for years while the demands of research -- and cost of funding it -- have increased.

Dr. Fauci said NIH will not concern itself with a project's direct pipeline into the economy because it assumes that all projects will provide additional jobs in the field. He said that for every one dollar put toward biomedical research, $2.50 is pumped into the economy.

About $7 billion of the stimulus money will go toward what Dr. Fauci termed "research priorities," while $1 billion will fund construction and capitol improvements at research universities.

Half a billion will go toward improving NIH buildings in Bethesda, Md..

Dr. Fauci's institute, which does research on HIV/AIDs, tuberculosis, influenza, and other infectious diseases, will receive a little over $1 billion, distributed among several funding areas.

The money will fund "challenge grants," which will include a project to examine what happens to a body in the early stages of HIV infection.

"A considerable amount of the immune system is destroyed in the first years, but we don't know how that works," Dr. Fauci said.

Other challenge grants will fund research to develop diagnostic tools for TB -- which infects one-third of the world's population -- and conduct research on neglected tropical diseases. (See NIH Announces New Rare Disease Drug Program)

Dr. Fauci also announced a new research project to test "big and bold" initiatives to stop the spread of HIV.

These include testing the effectiveness of pre-exposure prophylaxis on high-risk individuals, and a "test to treat" model, in which every person in a particular population is tested annually for HIV and treated immediately if the virus is detected.

Source.

Map - Lesbian and Gay Rights in the World - 2009 Edition

ILGA presents its 2009 version of its map on LGBTI rights in the world.

Founded in 1978, ILGA, the International Lesbian, Gay, Bisexual, Trans and Intersex Association is now a association of over 700 groups in over 110 countries campaigning for lesbian, gay, bisexual, trans and intersex (LGBTI) rights.

Sex Activist Wedad Lootah Challenges Taboos in Dubai

“Many men who had anal sex with men before marriage want the same thing with their wives, because they don’t know anything else,” Ms. Lootah said. “This is one reason we need sex education in our schools.




Challenging Sex Taboos, With Help From the Koran

via the New York Times, by Robert F. Worth

WEDAD LOOTAH does not look like a sexual activist. A Muslim and a native Emirati, she wears a full-length black niqab — with only her brown eyes showing through narrow slits — and sprinkles her conversation with quotes from the Koran.

Yet she is also the author of what for the Middle East is an amazingly frank new book of erotic advice in which she celebrates the female orgasm, confronts taboo topics like homosexuality and urges Arabs to transcend the backward traditions that limit their sexual happiness.

Read the rest.


Friday, June 5, 2009

EATG calls for more research and funding for prevention


The European AIDS Treatment Group (EATG) has recently released a comprehensive policy paper on HIV and AIDS prevention.

As a pan-European organisation of people living with HIV, EATG has been championing the concept of prevention, especially 'positive prevention' for years. Positive prevention entails the active involvement and leadership of people living with HIV and AIDS in prevention work.

EATG chair, Anna Zakowicz, states: ”Universal access to HIV prevention as well as treatment is necessary if we are to control the HIV epidemic globally and in Europe. No single prevention intervention is ever likely to stop the epidemic by itself and EATG therefore demands a comprehensive response involving social, behavioural, biomedical and structural interventions.”

People therefore need a varied package of prevention interventions which should include access to condoms (male and female) and access to sterile injecting equipment and opiod substitution therapy in all settings including prisons, information on HIV, behavioural support and interventions, and social support. EATG emphasises that it is important not to base HIV prevention and risk decisions on assumptions about the HIV status of partners and recommends continued awareness-raising of this point.

In addition, EATG urges more scientific research, and more funding allocation for research, into behaviour change and support programmes to populations living in Europe, especially marginalised and invisible groups. EATG supports continued research into new biomedical methods of prevention such as microbicides, pre-exposure prophylaxis (PrEP), prophylaxis against other sexually transmitted infections (STIs), and vaccines.

EATG considers that the HIV prevention needs of people already living with the virus have been neglected. Targeting HIV-positive people for prevention help and support is an equitable and cost-effective way of preventing HIV. EATG supports methods and technologies, which help to prevent HIV transmission between serodiscordant partners who have a desire for childbirth.

EATG supports initiatives to increase the proportion of people with HIV who are aware of their status. EATG advocates for counselling for every pregnant woman and encouragement and offer of voluntary HIV testing. It is also important to combat social, legal and cultural barriers against testing and disclosure, in particular the criminal prosecution of HIV transmission and exposure.

Click here for the paper (and note that IRMA is mentioned on page 18!)

Related Posts Plugin for WordPress, Blogger...